

Food and Drug Administration  
Center for Food Safety and Applied Nutrition  
Office of Special Nutritionals

ARMS#

13365



0 - FRONT

# MEDWATCH

THE FDA MEDICAL PRODUCTS REPORTING PROGRAM

For VOLUNTARY reporting  
by health professionals of adverse CFSA  
events and product problems

Form Approved: OMB No. 0910-0291 Expires: 12/31/94  
See OMB statement on reverse

FDA Use Only (MB)

Triage unit sequence #	97488
	13365

Page \_\_\_\_ of \_\_\_\_

## A. Patient information

1. Patient identifier [redacted] In confidence	2. Age at time of event: 49 or Date of birth: [redacted]	3. Sex <input checked="" type="checkbox"/> female <input type="checkbox"/> male	4. Weight 114 lbs or ____ kgs
--	--	---	--

## B. Adverse event or product problem

1. <input checked="" type="checkbox"/> Adverse event and/or <input type="checkbox"/> Product problem (e.g., defects/malfunctions)	
2. Outcomes attributed to adverse event (check all that apply)	
<input type="checkbox"/> death (mo/day/yr)	<input type="checkbox"/> disability
<input type="checkbox"/> life-threatening	<input type="checkbox"/> congenital anomaly
<input type="checkbox"/> hospitalization - initial or prolonged	<input type="checkbox"/> required intervention to prevent permanent impairment/damage
3. Date of event (mo/day/yr) 11/12/98	
4. Date of this report (mo/day/yr) 2/5/99	
5. Describe event or problem	

Patient used this product for 3 mo prior to 11/12/98. She developed an anemia + thrombocytopenia which resolved over 2 1/2 mo after the product was stopped

## 6. Relevant tests/laboratory data, including dates

See enclosed sheet

## 7. Other relevant history, including preexisting medical conditions (e.g., allergies, race, pregnancy, smoking and alcohol use, hepatic/renal dysfunction, etc.)

Asthma, Hay fever

Has used breathe tablets + alupent inhaler for years

## C. Suspect medication(s)

1. Name (give labeled strength & mfr/labeler, if known)		3. Therapy dates (if unknown, give duration) from/to (or best estimate)	
#1	Spark Nutritional Beverage	#1	8/15/98 - 11/12/98
#2		#2	
2. Dose, frequency & route used		4. Diagnosis for use (indication)	
#1		#1	
#2		#2	
5. Event abated after use stopped or dose reduced		8. Event reappeared after reintroduction	
#1	<input checked="" type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> doesn't apply	#1	<input type="checkbox"/> yes <input type="checkbox"/> no <input checked="" type="checkbox"/> doesn't apply
#2	<input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> doesn't apply	#2	<input type="checkbox"/> yes <input type="checkbox"/> no <input checked="" type="checkbox"/> doesn't apply
6. Lot # (if known)		7. Exp. date (if known)	
#1		#1	
#2		#2	
9. NDC # (for product problems only)			
10. Concomitant medical products and therapy dates (exclude treatment of event)			

## D. Suspect medical device

1. Brand name		4. Operator of device	
2. Type of device		<input type="checkbox"/> health professional <input type="checkbox"/> lay user/patient <input type="checkbox"/> other:	
3. Manufacturer name & address		5. Expiration date (mo/day/yr)	
6. model #		7. If implanted, give date (mo/day/yr)	
catalog #		8. If explanted, give date (mo/day/yr)	
serial #			
lot #			
other #			
9. Device available for evaluation? (Do not send to FDA)			
<input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> returned to manufacturer on (mo/day/yr)			
10. Concomitant medical products and therapy dates (exclude treatment of event)			

## E. Reporter (see confidentiality section on back)

1. Name & address		phone #	
[redacted]		[redacted]	
2. Health professional?		3. Occupation	
<input checked="" type="checkbox"/> yes <input type="checkbox"/> no		Internal Medicine	
4. Also reported to		5. If you do NOT want your identity disclosed to the manufacturer, place an "X" in this box. <input type="checkbox"/>	
<input type="checkbox"/> manufacturer <input type="checkbox"/> user facility <input type="checkbox"/> distributor			

000001



Mail to: MEDWATCH  
5600 Fishers Lane  
Rockville, MD 20852-9787  
or FAX to:  
1-800-FDA-0178

CTU 97488

PLEASE TYPE OR USE BLACK INK

# ADVICE ABOUT VOLUNTARY REPORTING

## Report experiences with:

- medications (drugs or biologics)
- medical devices (including in-vitro diagnostics)
- special nutritional products (dietary supplements, medical foods, infant formulas)
- other products regulated by FDA

## Report **SERIOUS** adverse events. An event is serious when the patient outcome is:

- death
- life-threatening (real risk of dying)
- hospitalization (initial or prolonged)
- disability (significant, persistent or permanent)
- congenital anomaly
- required intervention to prevent permanent impairment or damage

## Report even if:

- you're not certain the product caused the event
- you don't have all the details

## Report product problems – quality, performance or safety concerns such as:

- suspected contamination
- questionable stability
- defective components
- poor packaging or labeling

## How to report:

- just fill in the sections that apply to your report
- use section C for all products except medical devices
- attach additional blank pages if needed
- use a separate form for each patient
- report either to FDA or the manufacturer (or both)

## Important numbers:

- 1-800-FDA-0178 to FAX report
- 1-800-FDA-7737 to report by modem
- 1-800-FDA-1088 for more information or to report quality problems
- 1-800-822-7967 for a VAERS form for vaccines

**If your report involves a serious adverse event with a device** and it occurred in a facility outside a doctor's office, that facility may be legally required to report to FDA and/or the manufacturer. Please notify the person in that facility who would handle such reporting.

**Confidentiality:** The patient's identity is held in strict confidence by FDA and protected to the fullest extent of the law. The reporter's identity may be shared with the manufacturer unless requested otherwise. However, FDA will not disclose the reporter's identity in response to a request from the public, pursuant to the Freedom of Information Act.

The public reporting burden for this collection of information has been estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send your comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:

Reports Clearance Officer, PHS  
Hubert H. Humphrey Building,  
Room 721-B  
200 Independence Avenue, S.W.  
Washington, DC 20201  
ATTN: PRA

and to:  
Office of Management and  
Budget  
Paperwork Reduction Project  
(0910-0291)  
Washington, DC 20503

**Please do NOT  
return this form  
to either of these  
addresses.**

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Public Health Service • Food and Drug Administration

FDA Form 3500-back

**Please Use Address Provided Below – Just Fold In Thirds, Tape and Mail**

## Department of Health and Human Services

Public Health Service  
Food and Drug Administration  
Rockville, MD 20857

## Official Business

Penalty for Private Use \$300

## BUSINESS REPLY MAIL

FIRST CLASS MAIL PERMIT NO. 946 ROCKVILLE, MD

POSTAGE WILL BE PAID BY FOOD AND DRUG ADMINISTRATION

# MEDWATCH

The FDA Medical Products Reporting Program  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, MD 20852-9787

NO POSTAGE  
NECESSARY  
IF MAILED  
IN THE  
UNITED STATES  
OR APO/FPO

000002


Notes on Telephone Conversation  
Clinical Research and Review Staff

Date	5 March 99		Phone No.	[REDACTED]
Name	[REDACTED]	MD	Fax No.	
Affiliation				
Address	[REDACTED]			
FDA Representatives	Dr. Richard Calvert			
Question/Subject	F/u on ARMS 97488 - How many and which products was his patient using when the adverse event reported 2-5-99 occurred?			

Discussion	Dr. [REDACTED] spoke with me after I had identified myself as an FDA medical officer following up on his Med Watch report. He was unsure if his patient had used the other products (included were labels of these) along with "Spark Nutritional Beverage" he noted on the med watch form. He suggested I contact his patient directly, and gave me her telephone number.

Follow up	Will contact consumer with above question.

Signed:

  
Richard J. Calvert, MD

Date: 5 Mar 99

000003

Notes on Telephone Conversation  
Clinical Research and Review Staff

Date	5 Mar 99	Phone No.	[REDACTED]
Name	[REDACTED]	Fax No.	[REDACTED]
Affiliation	(consumer)		
Address			
FDA Representatives	Dr. Richard J. Calvert		
Question/Subject	F/U on ARMS # 97488 - Which supplement(s) were used prior to adverse event reported to Dr. [REDACTED]?		

Discussion	After obtaining permission from Dr. [REDACTED] I telephoned Mrs. [REDACTED] at her workplace & identified myself as an FDA Medical Officer. I asked her which supplements she was using prior to her adverse event. She told me she used 3 - the Spark Nutritional Beverage <sup>(once per day)</sup> , The Silver Packet (2 grey caplets, 1 brown caplet, 1 tan caplet) twice per day, and The White Packet (3 yellow caplets) once per day. She had used the 2 packets for about 6 months prior to the adverse event, and the Spark beverage for about 3 months prior to the adverse event. This usage was as described on the labels, except that she used the Spark beverage only once per day.
------------	---

Follow up	

Signed:

*Richard J. Calvert*

Date: 5 Mar 99

000004